Clinical Trial Update: Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating U29 Injection (CD30-CART) in CD30-positive relapsed or refractory lymphoma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• U29 Injection (CD30-targeted CAR-T cell therapy)

Snippet

Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Conditions: Relapsed or Refractory Lymphoma | Phase 1 | Status: RECRUITING